Form 4: Amphastar Pharmaceuticals CFO William Peters Executes Stock Option and Sells Shares
SEC Form 4 Filing
William Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, exercised stock options and sold shares on March 6, 2024, according to a Form 4 filing with the SEC.
Summary
- On March 6, 2024, William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, exercised stock options to acquire 8,826 shares of common stock at a price of $11.33 per share.
- Peters then sold 13,404 shares at a weighted average price of $46.2951, 4,681 shares at a weighted average price of $46.9762, and 51 shares at $48.
- Following these transactions, Peters directly owns 109,300 shares of Amphastar Pharmaceuticals common stock.
- 2,190 shares were withheld to cover tax liabilities related to the vesting of restricted stock units (RSUs).
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Insider trading activity is common across publicly listed companies, and the details of these transactions are reported on Form 4 filings.
- The use of Rule 10b5-1 trading plans is a standard practice to allow insiders to sell shares without being accused of trading on non-public information.
- Comparable companies in the pharmaceutical sector also have executives who regularly exercise stock options and sell shares, as part of their compensation and financial planning.
Stakeholder Impact
- The sale of shares by a key executive could be perceived negatively by some shareholders, although the existence of a pre-arranged trading plan mitigates this concern.
- The transactions have no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 06/05/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 03/06/2024 | Date of stock option exercise and share sales |
| 03/08/2024 | Date of signature on the Form 4 filing |
| 03/17/2026 | Expiration date of the employee stock option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.